Dr Harvey J Alter, Professor Paul Vincent Holland, Robert H Purcell and John L Gerin concluded that that RIA testing, which by then was available, was clearly more sensitive than CEP for revealing Hepatitis B surface antigen. Read more about Dr Harvey J Alter, Professor Paul Vincent Holland, Robert H Purcell and John L Gerin concluded that that RIA testing, which by then was available, was clearly more sensitive than CEP for revealing Hepatitis B surface antigen.
Dr Sheila Waiter noted that, "while it is generally accepted that the benefits of having Hemofil available for the treatment of bleeding episodes far out-weigh the risk of acquiring hepatitis B nevertheless the statement that 'every lot of this particular product is probably contaminated with hepatitis B virus' will come as a surprise to many clinicians using the product". Read more about Dr Sheila Waiter noted that, "while it is generally accepted that the benefits of having Hemofil available for the treatment of bleeding episodes far out-weigh the risk of acquiring hepatitis B nevertheless the statement that 'every lot of this particular product is probably contaminated with hepatitis B virus' will come as a surprise to many clinicians using the product".
Hospital Week reported a special message delivered by President Richard Nixon on Health Care in which he called for a a 'safe, fast and efficient blood collection and distribution system' arising from a general understanding by the authorities that the current system was inadequate; hospitals were often forced to buy blood which came from high risk donors such as drug addicts and derelicts. Read more about Hospital Week reported a special message delivered by President Richard Nixon on Health Care in which he called for a a 'safe, fast and efficient blood collection and distribution system' arising from a general understanding by the authorities that the current system was inadequate; hospitals were often forced to buy blood which came from high risk donors such as drug addicts and derelicts.
Dr Thomas was invited to speak at a meeting of the Scottish National Blood Transfusion Association.He is reported to have said, "Both the commercial products now licensed had come from factories inspected by DHSS; samples and protocols had been sent to the National Institute of Biological Standards and Quality Control...No British blood product underwent similar inspection." Read more about Dr Thomas was invited to speak at a meeting of the Scottish National Blood Transfusion Association.He is reported to have said, "Both the commercial products now licensed had come from factories inspected by DHSS; samples and protocols had been sent to the National Institute of Biological Standards and Quality Control...No British blood product underwent similar inspection."
Between 1970 and 1995 there were 144 Yellow Card reports relating to blood products on the Register of Adverse Reactions maintained by CSM. Read more about Between 1970 and 1995 there were 144 Yellow Card reports relating to blood products on the Register of Adverse Reactions maintained by CSM.
A product licence was granted to Cutter for Factor 8 heat-treated via pasteurisation. Read more about A product licence was granted to Cutter for Factor 8 heat-treated via pasteurisation.
In a memo to Dr Walford, Dr Oliver (DHSS) expressed the opinion that the assurance from pharmaceutical companies that future sales after June 1983 would comply with FDA guidelines was vague. Read more about In a memo to Dr Walford, Dr Oliver (DHSS) expressed the opinion that the assurance from pharmaceutical companies that future sales after June 1983 would comply with FDA guidelines was vague.
The Haemophilia Society planned a meeting with the junior Minister, Geoffrey Finsberg, to seek his assurance that there would be no immediate ban on the importation of US blood products. Read more about The Haemophilia Society planned a meeting with the junior Minister, Geoffrey Finsberg, to seek his assurance that there would be no immediate ban on the importation of US blood products.
A. W. Burrell (Managing Director, Travenol) wrote a letter to Dr Walford advising her that "well before" the FDA's 24 March recommendation, Hyland had taken steps to introduce screening procedures designed to eliminate high-risk donors. Read more about A. W. Burrell (Managing Director, Travenol) wrote a letter to Dr Walford advising her that "well before" the FDA's 24 March recommendation, Hyland had taken steps to introduce screening procedures designed to eliminate high-risk donors.
In a memo to Mr Wrigglesworth, Dr Fowler recorded the results of the FDA meeting held on 19 July 1983. The possibility of banning all products made before the FDA's March 1983 Regulations was rejected. Read more about In a memo to Mr Wrigglesworth, Dr Fowler recorded the results of the FDA meeting held on 19 July 1983. The possibility of banning all products made before the FDA's March 1983 Regulations was rejected.